Somerset, NJ February 21, 2012 — Michael Jenkins, Ph.D., General Manager of Catalent Pharma Solutions’ Middleton, WI facility, will present “Protein Expression in CHO Cells: Comparison of GPEx® to a Traditional Cell Line Engineering Technology” at the Cell Culture World Congress 2012 on Wednesday, February 29, 2012 in Munich, Germany.
Dr. Jenkins will give an account of how a large biotechnology organization compared a proprietary cell line development platform with its own internal resource, the impact on protein expression levels and the lessons learned from the collaboration.
Catalent helps customers achieve competitive advantage by producing stable, high-yielding mammalian cell lines, and by providing robust bio-manufacturing services with industry leading timelines.
Dr. Michael Jenkins has been with Catalent Pharma Solutions for more than nine years. Before becoming General Manager of Catalent’s Middleton, WI facility, he held senior roles in Commercial Operations and as Vice President of Business Development. Dr. Jenkins has previous industry experience in the development of mammalian cell culture and has also held technical roles at a plant transgenics company. He was awarded his Ph.D. by the Department of Molecular and Cellular Biology at the University of Arizona, with a minor in Biochemistry and has a B.S. in Microbiology from the University of Illinois at Champaign Urbana. Michael’s areas of interest include traditional and transgenic biologics manufacturing platforms, the evaluation and establishment of innovative technologies in the biotechnology marketplace and where these interests merge to reduce the cost of developing and manufacturing products.
Cell Culture World Congress 2012 runs from Wednesday, February 28th to March 1st. Dr Jenkins’ presentation will take place at 09.40 am on day two of the Congress at the Westin Grand Munchen, Munich, Germany. For more information on this event, please visit www.terrapinn.com/2012/cellculture.
To schedule an interview with Dr. Jenkins during or after the conference, please contact Patricia McGee or Chris Halling at media@catalent.com.
To receive a copy of this presentation after the event, please visit us at www.catalent.com.
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com
more products. better treatments. reliably supplied.™
Media Contacts:
Christopher Halling
T +44 (0) 7580 041073
chris.halling@catalent.com
Patricia McGee
T +1 (732) 537 6407
patricia.mcgee@media.com
